Physician profile
Caesar Deiparine
NPI 1174529408
$1,284.29
in general payments reported to CMS, 2019-2025
19 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $67.64 · 2021: $50.63 · 2022: $109 · 2023: $264 · 2024: $206 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $193.06 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $178.64 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $119.08 | 2019-2025 | |
| Abbvie INC. | $96.80 | 2022-2024 | Qulipta, Ubrelvy |
| Exact Sciences Corporation | $89.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sk Life Science, INC. | $88.66 | 2020-2021 | |
| Lilly USA, LLC | $76.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $74.68 | 2019-2020 | |
| Amgen INC. | $67.33 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $41.05 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $36.94 | 2019 | |
| Dexcom, INC. | $33.92 | 2024-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $30.87 | 2023 | Austedo |
| Astellas Pharma US INC | $28.48 | 2019-2024 | Veozah |
| Neurelis, INC. | $27.82 | 2025 | Valtoco |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.32 | 2023 | Spravato |
| Radius Health, INC. | $25.52 | 2023 | Tymlos |
| Collegium Pharmaceutical, INC. | $24.50 | 2022 | |
| Genzyme Corporation | $24.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caesar Deiparine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.